
    
      A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability,
      Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Non-Hodgkin B-cell
      Lymphoma. This study includes dose escalation (Part A) and dose expansion (Part B).
    
  